Objective To develop a set of core outcomes for studies on pregnant women with epilepsy.
Introduction
Epilepsy, one of the most common neurological conditions in pregnancy, is associated with maternal and offspring mortality and morbidity. 1 Women with epilepsy are at an increased risk of neurological and obstetric complications such as uncontrolled seizures and preterm birth. 2 Their offspring are at risk of congenital abnormalities, growth restriction, and long-term neurodevelopmental delay. 3 Currently, clinical studies on epilepsy in pregnancy vary widely in the nature and quality of the outcomes, 4 which is undesirable. There is no consensus on the main outcomes to be reported in studies on women with epilepsy.
The outcomes evaluated in studies should be important to stakeholders such as healthcare professionals, policy makers, and mothers for it to be relevant in evidence-based practice. Many of the outcomes reported are chosen by healthcare professionals, such as neurological events in pregnancy. 4 There is little focus on the outcomes of concern to women, such as breastfeeding and quality of life. The current variation observed in reported outcomes hinders the synthesis of evidence, and limits the precision and applicability of findings in clinical guidelines. 4, 5 There is a need to generate a set of core outcomes to be reported in studies on pregnant women with epilepsy. To achieve this, consensus should be reached among different stakeholders involved in the care of women with epilepsy, as well as patient representatives. 6 We undertook a UKwide multistakeholder modified Delphi method to develop consensus on a set of core outcomes for reporting in clinical studies on pregnant women with epilepsy.
Methods
We conducted an electronic modified Delphi method including various stakeholders involved in the care of pregnant women with epilepsy. Patient representatives were included in the process, in line with recommended methods. 7 A prospective study protocol was registered in the Core Outcome Measures in Effectiveness Trials (COMET) database.
8 A dedicated core management group was responsible for the overall conduct of the study (BHA, KT, KSK, and ST). Members of the core group took part in the survey anonymously. We reported the study following the COMET recommendations (Appendix S1). 9 
Identification of outcomes
We undertook a systematic review of all studies on pregnant women with epilepsy to create a long list of clinically relevant outcomes. 4 We searched the major electronic databases of MEDLINE, Embase, CINAHL, AMED, and the Cochrane Library (1999-January 2015) for studies on women with epilepsy. We included all primary studies reporting on outcomes for pregnant women with epilepsy of all study designs. Outcomes were extracted by two independent reviewers into an electronic standardised data collection tool. The study core management group categorised the outcomes into three main domains: maternal neurological, offspring, and obstetric outcomes. Any disagreement in categorising the identified outcomes was resolved by consensus between the group members, through face-to-face discussions. We combined outcomes that were clinically and pathophysiologically similar, to improve the ease of response to the Delphi method. For example, placenta praevia and placenta accreta were grouped under placental abnormalities. Similarly, venous thrombotic events were also combined as one outcome. The core outcome list was sent to the participants to rate the outcomes for their clinical importance in the evaluation of pregnant women with epilepsy. Additionally, we asked participants to report any other relevant outcomes that were not included in the initial list. All outcomes were included in all rounds of the modified Delphi method. Lay definitions of outcomes were generated for the patient representative survey using the University of Michigan Simplification Guide to Medical Terms. 10 
Survey participants
We included participants from the following stakeholder groups: obstetricians and midwives; neurologists and epilepsy nurses; neonatologists; and patient representatives. We identified healthcare professionals from the National Collaborators group of the Antiepileptic Drug Monitoring in Pregnancy (EMPIRE) study. 11 Participants were identified via direct email invitations using the EMPIRE investigators' email database. Participants were either principal investigators with experience in clinical trials on pregnant women with epilepsy or clinical experts in this field. We identified patient representatives with the help of the UK national epilepsy charity, Epilepsy Action, via an electronic advert on the charity website, as well as sending an invitation in the charity newsletter.
12
Patient representatives were identified as women who had lived the experience of epilepsy in pregnancy, their family members, such as partners, or individuals with significant experience in caring for women with epilepsy, such as campaign coordinators from the Epilepsy Action charity.
Modified Delphi method
We sent invitations to all participants by email. Initially we sent them questionnaires using Survey Monkey software (surveymonkey.com). In subsequent rounds we used direct email questionnaires based on feedback from participants. We predefined non-responders as those participants who did not complete the survey despite three email reminders. We did not include non-responders in subsequent rounds, but they were invited to the final consultation meeting.
We asked participants to use a five-point Likert scale to rank each outcome for its clinical importance (anchored between 1 as least important and 5 as most important). A score of 1 was considered to be least important; a score of 5 was considered to be most important or critical. The scores of the individual participants were kept anonymous throughout the survey. At the end of each round, we provided the mean scores and standard deviations for each outcome to all participants, to enable reflection before completion of the subsequent round. Additionally, at the end of the second round we provided the scores by each stakeholder group. Results were then fed back to participants using numerical tables. All three rounds were moderated by the same researcher (BHA). Patient representatives completed only one survey round. Their responses were included in the final analysis.
We pre-specified the criteria for inclusion of outcomes into the core set: score of ≥4 by more than 70% of participants and a score of ≤2 by less than 15% of participants. Outcomes were excluded if they received a score of ≥4 by less than 15% of participants and a score of ≤2 by more than 70% of participants. Outcomes that did not fulfil either of the two criteria were considered equivocal, and were taken forwards for discussion in a consultation meeting.
Consultation meeting
We held a consultation meeting at the end of the survey to finalise the core outcome set. The consultation meeting discussed outcomes that were equivocal in the modified Delphi method. All participants in the modified Delphi method, from all stakeholder groups, were invited to attend the consultation meeting. We used a mobile phone-based electronic voting system to assess consensus between the participants at the meeting. 13 The meeting included two rounds. The first round screened the list of equivocal outcomes and identified those needing detailed discussion, and the second round selected the outcomes for inclusion in the final core outcome set. We used the same criteria as those for the modified Delphi method to determine consensus in the consultation meeting.
Data analysis
We entered participants' scores into an electronic EXCEL sheet at the end of each round. We calculated the mean and standard deviation of the scores for each outcome. All statistical analyses were conducted using Microsoft Excel 2007 (Microsoft Corp., Redmond, WA, USA) and SPSS 19 (IBM Inc., New York, NY, USA).
Results
Seventy-five participants completed the first round (47 obstetricians and midwives, 14 neurologists and epilepsy nurses, and 14 neonatologists). In the second round, twothirds (48/75, 64%) completed the survey (25 obstetricians and midwives, ten neurologists and epilepsy nurses, and 13 neonatologists). And half of all participants (37/75, 49.3%) completed the third round of the survey (20 obstetricians and midwives, six neurologists and epilepsy nurses, and 11 neonatologists). Twenty-four patient representatives completed their round of the survey. The final consultation group comprised obstetricians, midwives, neurologists, epilepsy specialist nurses, neonatologists, patient representatives, and researchers ( Table 1 ). The characteristics of the study participants are reported in Appendix S2.
Prioritisation of outcomes
Our systematic review identified 70 different outcomes, which were reported in 232 primary studies on epilepsy in pregnancy. 4 After grouping the initial list included 48 outcomes; 30 outcomes reached consensus in the first round for their clinical importance (30/48, 62.5%), and a third (18/48, 37.5%) were considered to be of equivocal importance. In the second round, consensus was reached for 25 outcomes (25/48, 52.0%), and about half (23/48, 47.9%) were equivocal. In the final round, 21 outcomes (21/48, 43.7%) were identified as important by consensus, and over half (27/48, 56.2%) were equivocal. Patient representatives considered 40 outcomes (40/48, 83.3%) to be important, and the rest of the outcomes as equivocal (8/48, 16.6%).
At the end of the modified Delphi method, 24 outcomes were considered to be important for inclusion in the core outcome set, and 24 outcomes were seen as equivocal (Table S1 ). These included nine maternal neurological outcomes: seven were relevant to all women with epilepsy, such as seizure control, status epilepticus, sudden unexpected death in epilepsy (SUDEP), maternal death, postnatal depression, quality of life, and drowning; two were only applicable for studies on women exposed to AEDs, such as maternal toxicity from AED and compliance with AED intake. The eight important offspring outcomes included six general outcomes such as major and minor congenital 
Consultation meeting
In the first round, the panel discussed the equivocal outcomes. After the first round of voting, four outcomes were chosen for further detailed discussion. These were anthropometric measurements, including birthweight, preterm birth, pre-eclampsia, and mode of delivery. Termination of pregnancy was included in the pregnancy viability outcomes, as it was judged to be important by the panel. A further two additional outcomes, postpartum seizure control and neonatal haemorrhagic disease, were recommended for further evaluation. In the second voting round, all seven outcomes reached consensus and were included in the core outcome set. The final core set included 31 outcomes: ten maternal neurological, ten offspring, and 11 obstetric outcomes. Of these, four were specific for studies on pregnant women taking anti-epileptic medications, and one was specific for studies with long-term follow-up. Table 2 provides the list of the individual outcomes in various domains.
Discussion

Main findings
Our study is the first to identify a set of core outcomes for reporting in studies on pregnant women with epilepsy. The final set of outcomes has incorporated all reported epilepsy-related outcomes in neurology, obstetrics, and neonatology by involving the relevant stakeholders, including patient representatives. The patient representatives led to the inclusion of outcomes important to pregnant women, such as quality of life, postnatal depression, and drowning, which were not well reported in current studies.
Strengths and limitations
We used a robust methodology to capture the whole range of outcomes to reach consensus. We used predefined criteria for the inclusion of outcomes into the core set. The modified Delphi method allowed us to maintain the anonymity of participants, and thereby avoid the overt influence of particular individuals or stakeholder groups on the final score.
14 The Delphi technique has been widely used to develop core outcome sets and to generate consensus between stakeholders. 7 Participation was voluntary, and all participants were informed that they could withdraw from the survey at any stage. A sizable proportion of patient representatives were involved in the survey, and in the consultation process. The Neonatal withdrawal symptoms* Compliance with anti-epileptic drug intake* Neonatal haemorrhagic disease* *Outcomes applicable only in studies on pregnant women on anti-epileptic drugs. **Acute respiratory distress syndrome, anaemia, hypoglycaemia, hyperglycaemia, hypocalcaemia, hypotonia, feeding problems, sedation syndrome, icterus/convulsions, cephalhaematoma, and Apgar scores. ***Relevant for studies with long-term follow-up.
final consultation meeting provided an interactive forum for stakeholders to agree on equivocal outcomes, and to discuss any previously missed outcomes. Our results were limited by the progressive attrition in the modified Delphi method. The attrition was greatest after the first round, and was lower in the second round. This is not unexpected with the use of multiple survey rounds. 15 The high attrition rate in patient representatives limited their inclusion to one round only. We intended to involve patient representatives in all three rounds of the survey; however, this was not possible within the study timeline. In view of the increased emphasis on including patients' views in the development of core outcomes, 16 we resolved to include their input in the final consultation meeting. The convergence of scores for the outcomes was a slow process as the survey progressed, indicating the difficulty experienced by the participants in assessing the importance of each outcome. Our systematic review highlighted a large number of outcomes on neonatal clinical complications with varied outcome measures: for example, jaundice can be reported using biochemical measures or clinical severity. 4 Including each of these outcomes independently into our Delphi survey was outside the scope of this project. We resolved to group them all together under one outcome domain in the Delphi survey. Further consensus work is needed to standardise outcome reporting, and the individual ranking of outcome measures in this field may have identified fewer components. Some of the core outcomes identified are only applicable to studies on pregnant women on AEDs, such as maternal toxicity and fetal anticonvulsant syndrome. It is possible that the generalisability of our findings is limited to settings in developed countries, as our survey just targeted stakeholders from the UK.
Interpretation
Maternal neurological outcomes
The maternal neurological outcomes identified reflect the findings of the recent Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries acroos the UK (MBRRACE-UK) report on confidential enquiries into maternal deaths (2009) (2010) (2011) (2012) , which emphasised the need to prioritise both the antenatal and the postnatal care of women with epilepsy. 17 In addition to the outcomes prioritised by the survey, such as seizure deterioration in pregnancy, the consensus panel additionally prioritised postpartum seizure control. Postnatal seizures are often exacerbated by many factors, such as sleep deprivation or non-compliance with AED intake because of concerns for the safety of the baby in breastfeeding mothers. 18 Additionally, we identified quality of life and postnatal depression as important outcomes, which were rated as critically important by most patient representatives as well as healthcare professionals.
Offspring outcomes
We identified traditionally well-reported outcomes such as congenital malformation in the fetus. Additionally, clinical complications in the newborn and specific outcomes, including neonatal haemorrhagic disease, were included. The panel acknowledged the paucity of evidence on the association of AED exposure in utero and the risk of neonatal bleeding caused by decreased levels of vitamin K, 19 leading to the inclusion of this important additional outcome. Some core outcomes such as neurodevelopment of the offspring and autism spectrum disorder require long-term follow-up. The inclusion of all relevant outcomes will ensure that the health of both mother and baby is given equal importance, thus minimising research wastage. We acknowledge that including such long-term outcomes may not be feasible for all future studies; however, researchers are prompted to consider and reflect on the proposed core outcome set covering this issue in the discussion section of their papers. They may use the power inherent in multi-stakeholder consensus to justify the need for funding in order to persuade grant-giving bodies.
Obstetric outcomes
The stakeholders felt that five separate outcomes for fetal viability (live births, stillbirth, miscarriage, ectopic pregnancy, and termination of pregnancy) should be reported. Termination of pregnancy was judged by the panel to be a surrogate for major or minor abnormalities, and also reflective of maternal concerns as a result of epilepsy and AED exposure. 2 Preterm birth, caesarean section, and preeclampsia are significantly associated with epilepsy, 1 and have been included in the core outcome set. Eclampsia, a condition with seizures in pregnancy, is one of the main differential diagnoses of epilepsy, and was also included in the core set. The safety of breastfeeding while taking AEDs is understandingly a major worry for mothers, and our knowledge on the potential risks to their offspring is still limited. 20 Our participants have identified this as an important outcome.
Implications for research and clinical practice
The standardised reporting of core outcomes identified across all studies will help in improving the quality of evidence synthesis, and will enable researchers to combine and compare results from different studies. Further research is needed on the development of validated assessment tools in pregnancy for women with epilepsy, particularly for outcomes such as quality of life in pregnancy and postnatal depression. We acknowledge that including all identified core outcomes might not be feasible for all future studies because of funding limitation or high attrition rate. We encourage researchers to consider all of the outcomes identified in this core set and to provide a critical account on all excluded outcomes at the study design stage.
Conclusion
Embedding this core set in future clinical trials will promote the standardisation of reporting to inform clinical practice.
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